Provention Bio to Report Third Quarter 2021 Financial Results on November 4, 2021

Rhea-AI Summary

Provention Bio, Inc. (Nasdaq: PRVB) will release its third quarter 2021 financial results on November 4, 2021, before the U.S. markets open. Following this, a conference call is scheduled for 8:00 am E.T. to discuss the results and provide corporate updates. The company focuses on investigational therapies for immune-mediated diseases, including type 1 diabetes and celiac disease. For call access, dial 1-888-347-7861 or join via their website for an audio webcast. More information is available at www.proventionbio.com.

RED BANK, N.J., Oct. 28, 2021 /PRNewswire/ -- Provention Bio, Inc. (Nasdaq: PRVB), a biopharmaceutical company dedicated to intercepting and preventing immune-mediated disease, today announced that it will report its third quarter 2021 financial results on Thursday, November 4, 2021, before the opening of the U.S. financial markets. Subsequently, at 8:00 am E.T., the company will host a conference call to discuss its financial results and provide a corporate update.

To access the call, please dial 1-888-347-7861 (domestic) or 1-412-902-4247 (international) ten minutes prior to the start time and ask to be connected to the "Provention Bio Call." An audio webcast will also be available on the "Events and Webcasts" page of the Investors section of the Company's website, www.proventionbio.com. An archived webcast will be available on the Company's website approximately two hours after the conference call.

About Provention Bio, Inc.:

Provention Bio, Inc. (Nasdaq: PRVB) is a biopharmaceutical company focused on advancing the development of investigational therapies that may intercept and prevent debilitating and life-threatening immune-mediated disease. The Company's pipeline includes clinical-stage product candidates that have demonstrated in pre-clinical or clinical studies proof-of-mechanism and/or proof-of-concept in autoimmune diseases, including type 1 diabetes, celiac disease and lupus. Visit www.ProventionBio.com for more information and follow us on Twitter: @ProventionBio.

Internet Posting of Information:

Provention Bio, Inc. uses its website, www.proventionbio.com, as a means of disclosing material nonpublic information and for complying with its disclosure obligations under Regulation FD. Such disclosures will be included on the Company's website in the "News" section. Accordingly, investors should monitor this portion of the Company's website, in addition to following its press releases, SEC filings and public conference calls and webcasts.

Investor Contacts:
Robert Doody, VP of Investor Relations
rdoody@proventionbio.com
484-639-7235

Sam Martin, Argot Partners
sam@argotpartners.com  
212-600-1902

Media Contact:
Lori Rosen, LDR Communications
lori@ldrcommunications.com
917-553-6808

View original content to download multimedia:https://www.prnewswire.com/news-releases/provention-bio-to-report-third-quarter-2021-financial-results-on-november-4-2021-301410473.html

SOURCE Provention Bio, Inc.

FAQ

When will Provention Bio release its Q3 2021 financial results?

Provention Bio will report its Q3 2021 financial results on November 4, 2021.

What time is the Provention Bio conference call scheduled?

The conference call is scheduled for 8:00 am E.T. on November 4, 2021.

How can I access the Provention Bio conference call?

To access the call, dial 1-888-347-7861 domestically or 1-412-902-4247 internationally, or join the audio webcast on their website.

What is Provention Bio focused on?

Provention Bio focuses on developing investigational therapies for immune-mediated diseases such as type 1 diabetes and celiac disease.